In one aspect, provided herein is use of a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer.

In another aspect, provided herein is use of:

a pharmaceutical composition comprising a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient; and

a pharmaceutical composition comprising an EGFR inhibitor, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient,

in the manufacture of a medicament for treating cancer.

In another aspect, provided herein is use of a KRAS G12D inhibitor that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor that is cetuximab in the manufacture of a medicament for treating cancer.

In another aspect, provided herein is use of a KRAS G12D inhibitor that is methyl (1*R*,3*R*,4*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor that is cetuximab in the manufacture of a medicament for treating cancer.

In another aspect, provided herein is a pharmaceutical composition comprising

a) a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof;

b) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof; and

c) at least one pharmaceutically acceptable carrier or excipient.

In another aspect, provided herein is a pharmaceutical combination comprising a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor, or pharmaceutically acceptable salt thereof.

CLAIMS

What is claimed is:

1. Use of a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor, or pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer.

2. The use of claim 1, wherein the EGFR inhibitor is an anti-EGFR antibody.

3. The use of claim 1 or 2, wherein the EGFR inhibitor is selected from cetuximab, matuzumab, necitumumab, nimotuzumab, panitumumab, and zalutumumab.

4. The use of any one of claims 1 to 3, wherein the EGFR inhibitor is cetuximab.

5. The use of claim 1, wherein the EGFR inhibitor is a small molecule inhibitor.

6. The use of claim 1 or 5, wherein the EGFR inhibitor is selected from afatinib, brigatinib, dacomitinib, erlotinib, gefitinib, icotinib, lapatinib, mobocertinib, neratinib, osimertinib, and vandetanib.

7. The use of any one of claims 1 to 6, wherein the G12D inhibitor has an IC_{50} of about 100 nM or lower.

8. The use of any one of claims 1 to 7, wherein the G12D inhibitor is selective for inhibiting G12D versus wild-type KRAS.

9. The use of any one of claims 1 to 8, wherein the KRAS G12D inhibitor is a compound of Formula I:



I

or a pharmaceutically acceptable salt thereof, wherein:

Y is N or CR^6;

R^1 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, cyclopropyl, halo, D, CN, and OR^{a1}; wherein said C_{1-3} alkyl and cyclopropyl are each optionally substituted with 1 or 2 substituents independently selected from R^g;

R^2 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, 5-6 membered heteroaryl-C_{1-3} alkylene, halo, D, CN, and OR^{a2}; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, 5-6 membered heteroaryl-C_{1-3} alkylene are each optionally substituted with 1 or 2 substituents independently selected from R^g;

Cy^1 is selected from C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl; wherein the 4-10 membered heterocycloalkyl and 6-10 membered heteroaryl each has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 6-10 membered heteroaryl and 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{10};

R^3 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, 5-6 membered heteroaryl-C_{1-3} alkylene, halo, D, CN, OR^{f3}, $C(O)NR^{c3}R^{d3}$, $NR^{c3}R^{j3}$, and $NR^{c3}C(O)R^{b3}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, and 5-6 membered heteroaryl-C_{1-3} alkylene are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

R^5 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, cyclopropyl, halo, D, CN, and OR^{a5}; wherein said C_{1-3} alkyl and cyclopropyl are each optionally substituted with 1 or 2 substituents independently selected from R^g;

R^6 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, 5-6 membered heteroaryl-C_{1-3} alkylene, halo, D, CN, OR^{a6}, and $C(O)NR^{c6}R^{d6}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-9 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, and 5-6 membered heteroaryl-C_{1-3} alkylene are each optionally substituted with 1 or 2 substituents independently selected from R^{60};

R^7 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, cyclopropyl, halo, D, CN, and OR^{a7}; wherein said C_{1-3} alkyl and cyclopropyl are each optionally substituted with 1 or 2 substituents independently selected from R^g;

Cy^2 is selected from



and



;

Cy^2-a Cy^2-b

wherein n is 0, 1, or 2;

each R^{10} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a10}, $C(O)R^{b10}$, $C(O)NR^{c10}R^{d10}$, $C(O)OR^{a10}$, $NR^{c10}R^{d10}$, and $S(O)_2R^{b10}$;

each R^{20} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, and OR^{a20};

each R^{30} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a30}, $C(O)R^{b30}$, $C(O)NR^{c30}R^{d30}$, $C(O)OR^{a30}$, $NR^{c30}R^{d30}$, and $S(O)_2R^{b30}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{31};

each R^{31} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a31}, $C(O)R^{b31}$, $C(O)NR^{c31}R^{d31}$, $C(O)OR^{a31}$, $NR^{c31}R^{d31}$, and $S(O)_2R^{b31}$;

each R^{33} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-membered heterocycloalkyl, 6-membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a30}, $C(O)NR^{c30}R^{d30}$, and $NR^{c30}R^{d30}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-membered heterocycloalkyl, 6-membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{31};

each R^{60} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a60}, $C(O)R^{b60}$, $C(O)NR^{c60}R^{d60}$, $NR^{c60}C(O)R^{b60}$, $C(O)OR^{a60}$, $NR^{c60}C(O)OR^{a60}$, $NR^{c60}R^{d60}$, $NR^{c60}S(O)_2R^{b60}$, and $S(O)_2R^{b60}$; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

each R^{61} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a61}, and $NR^{c61}R^{d61}$;

R^{a1} is selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a2} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{b3}, R^{c3} and R^{d3} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said , C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

or R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

R^{j3} is selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said , C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

or R^{c3} and R^{j3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

R^{f3} is selected from C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30}; or

R^{f3} is selected from



, and



;

R^{f3}-a R^{f3}-b

wherein R^x is H or C_{1-2} alkyl and R^y is C_{1-2} alkyl;

or R^x and R^y, together with the C atom to which they are attached, form a 3-, or 4-membered cycloalkyl group;

R^{a5} is selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a6}, R^{c6} and R^{d6} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{60};

R^{a7} is selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a10}, R^{b10}, R^{c10} and R^{d10} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a20} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

R^{b20} is selected from NH_2, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a30}, R^{b30}, R^{c30} and R^{d30} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a31}, R^{b31}, R^{c31} and R^{d31} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a60}, R^{b60}, R^{c60} and R^{d60} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

or any R^{c60} and R^{d60} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R^{61}; and

each R^{a61}, R^{c61}, and R^{d61}, is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each R^g is independently selected from D, OH, CN, halo, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{1-3} haloalkoxy, amino, C_{1-3} alkylamino, and di(C_{1-3} alkyl)amino.

10. The use of claim 9, wherein

Y is CR^6;

R^1 is selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

R^2 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, and OR^{a2}; wherein said C_{1-3} alkyl is optionally substituted with 1 or 2 substituents independently selected from R^g;

Cy^1 is selected from C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl; wherein the 4-10 membered heterocycloalkyl and 6-10 membered heteroaryl each has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of 6-10 membered heteroaryl and 4-10 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{10};

R^3 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, $C(O)NR^{c3}R^{d3}$, and $NR^{c3}C(O)R^{b3}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

R^5 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, and halo;

R^6 is selected from H, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a6}, and $C(O)NR^{c6}R^{d6}$; wherein said C_{3-6} cycloalkyl, 4-8 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{60};

R^7 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, and CN;

Cy^2 is selected from



,

and



;

Cy^2-a Cy^2-b

wherein n is 0, 1, or 2;

each R^{10} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a10}, $C(O)R^{b10}$, $C(O)NR^{c10}R^{d10}$, $C(O)OR^{a10}$, $NR^{c10}R^{d10}$, and $S(O)_2R^{b10}$;

each R^{20} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, and OR^{a20};

each R^{30} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a30}, $C(O)R^{b30}$, $C(O)NR^{c30}R^{d30}$, $C(O)OR^{a30}$, $NR^{c30}R^{d30}$, and $S(O)_2R^{b30}$; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{31};

each R^{31} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a31}, $C(O)R^{b31}$, $C(O)NR^{c31}R^{d31}$, $C(O)OR^{a31}$, $NR^{c31}R^{d31}$, and $S(O)_2R^{b31}$;

each R^{60} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a60}, $C(O)R^{b60}$, $C(O)NR^{c60}R^{d60}$, $NR^{c60}C(O)R^{b60}$, $C(O)OR^{a60}$, $NR^{c60}C(O)OR^{a60}$, $NR^{c60}R^{d60}$, $NR^{c60}S(O)_2R^{b60}$, and $S(O)_2R^{b60}$; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

each R^{61} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, OR^{a61}, and $NR^{c61}R^{d61}$;

each R^{a2} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{b3}, R^{c3} and R^{d3} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said , C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered

heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

or R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

each R^{a6}, R^{c6} and R^{d6} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{60};

each R^{a10}, R^{b10}, R^{c10} and R^{d10} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a20} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

R^{b20} is selected from NH_2, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a30}, R^{b30}, R^{c30} and R^{d30} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a31}, R^{b31}, R^{c31} and R^{d31} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a60}, R^{b60}, R^{c60} and R^{d60} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

or any R^{c60} and R^{d60} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R^{61}; and

each R^{a61}, R^{c61}, and R^{d61}, is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl; and

each R^{g} is independently selected from D, CN, halo, C_{1-3} alkyl, and C_{1-3} haloalkyl.

11. The use of claim 9 or 10, wherein

Y is CR^6;

R^1 is H;

R^2 is selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, and $-CH_2CH_2CN$;

Cy^1 is selected from C_{3-10} cycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl; wherein the 6-10 membered heteroaryl has at least one ring-forming carbon atom and 1, ring-forming heteroatoms independently selected from N and S; and wherein the C_{3-10}

cycloalkyl, C_{6-10} aryl and 6-10 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{10};

R^3 is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{30};

R^5 is selected from H and halo;

R^6 is selected from H, C_{1-3} haloalkyl, 4-8 membered heterocycloalkyl, and 5-6 membered heteroaryl; wherein said 4-8 membered heterocycloalkyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{60}; or

R^7 is halo;

Cy^2 is



;

Cy^2-b

each R^{10} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, D, CN, and OR^{a10};

each R^{30} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, 4-6 membered heterocycloalkyl, halo, D, CN, OR^{a30}, $C(O)NR^{c30}R^{d30}$, and $NR^{c30}R^{d30}$; wherein said C_{1-3} alkyl and 4-6 membered heterocycloalkyl are each optionally substituted with 1 or 2 substituents independently selected from R^{31};

each R^{31} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, CN, OR^{a31}, and $NR^{c31}R^{d31}$;

each R^{60} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a60}, $C(O)R^{b60}$, $C(O)NR^{c60}R^{d60}$, $NR^{c60}C(O)R^{b60}$, $C(O)OR^{a60}$, $NR^{c60}C(O)OR^{a60}$, $NR^{c60}R^{d60}$, $NR^{c60}S(O)_2R^{b60}$, and $S(O)_2R^{b60}$; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

each R^{61} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, and CN;

each R^{a10} is independently selected from H and C_{1-3} alkyl;

each R^{a30}, R^{c30} and R^{d30} is independently selected from H and C_{1-3} alkyl;

each R^{a31}, R^{c31} and R^{d31} is independently selected from H and C_{1-3} alkyl;

each R^{a60}, R^{b60}, R^{c60} and R^{d60} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl;

wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

or any R^{c60} and R^{d60} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R^{61}.

12. The use of any one of claims 9 to 11, wherein

Y is CR^6;

R^1 is H;

R^2 is $-CH_2CH_2CN$;

Cy^1 is phenyl; wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from R^{10};

R^3 is selected from H, C_{1-3} alkyl, phenyl, and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1, 2 or 3 substituents independently selected from R^{30};

R^5 is selected from H and halo;

R^6 is selected from 4-8 membered heterocycloalkyl; wherein said 4-8 membered heterocycloalkyl is optionally substituted with 1 or 2 substituents independently selected from R^{60}; or

R^6 is selected from C_{1-3} alkyl; wherein said C_{1-3} alkyl is substituted with 1 or 2 substituents independently selected from R^{60};

R^7 is halo;

Cy^2 is



;

Cy^2-b

each R^{10} is independently selected from C_{1-3} alkyl and halo;

each R^{30} is independently selected from C_{1-3} alkyl, halo, D, OH, and $C(O)NR^{c30}R^{d30}$; wherein said C_{1-3} alkyl is optionally substituted with 1 substituent independently selected from R^{31};

each R^{31} is OR^{a31};

each R^{60} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkoxy, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, halo, $C(O)R^{b60}$, $C(O)NR^{c60}R^{d60}$, $NR^{c60}C(O)R^{b60}$, $C(O)OR^{a60}$, $NR^{c60}C(O)OR^{a60}$, and $NR^{c60}S(O)_2R^{b60}$; wherein said C_{1-3} alkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

each R^{61} is independently selected from C_{1-3} alkyl, and halo;

each R^{c30} and R^{d30} is independently selected from H and C_{1-3} alkyl;

each R^{a31} is independently selected from H and C_{1-3} alkyl; and

each R^{a60}, R^{b60}, R^{c60} and R^{d60} is independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl; wherein said C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

or any R^{c60} and R^{d60} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1 or 2 substituents independently selected from R^{61}.

13. The use of any one of claims 9 to 12, wherein

Y is CR^6;

R^1 is H;

R^2 is $-CH_2CH_2CN$;

Cy^1 is phenyl; wherein the phenyl is optionally substituted with 1 or 2 substituents independently selected from R^{10};

R^3 is selected from H, methyl, ethyl, phenyl, 1,2,4-triazolyl, pyrazyl, and pyridyl; wherein said methyl, phenyl, 1,2,4-triazolyl, pyrazyl, and pyridyl are each optionally substituted with 1, 2 or 3 substituents independently selected from R^{30};

R^5 is selected from H and chloro;

R^6 is selected from pyrrolidinyl, 2-azabicyclo[3.1.0]hexanyl, 2-azabicyclo[2.2.1]heptanyl, and 5-oxo-1,2,3,5-tetrahydroindolizin-3-yl; wherein said pyrrolidinyl, 2-azabicyclo[3.1.0]hexanyl, 2-azabicyclo[2.2.1]heptanyl ,and 5-oxo-1,2,3,5-tetrahydroindolizin-3-yl are optionally substituted with 1 or 2 substituents independently selected from R^{60};

R^7 is fluoro;

Cy^2 is



;

Cy^2-b

each R^{10} is independently selected from methyl, fluoro, and chloro;

each R^{30} is independently selected from methyl, fluoro, OH, D, and $C(O)NR^{c30}R^{d30}$; wherein said methyl is optionally substituted with 1 substituent that is R^{31};

each R^{31} is OR^{a31};

each R^{60} is independently selected from methyl, fluoro, C_{1-2} haloalkoxy, 3-oxomorpholinyl, 2-oxopyrazin-1(2*H*)-yl), $C(O)R^{b60}$, $C(O)NR^{c60}R^{d60}$, $NR^{c60}C(O)R^{b60}$, $C(O)OR^{a60}$, $NR^{c60}C(O)OR^{a60}$, and $NR^{c60}S(O)_2R^{b60}$; wherein said 3-oxomorpholinyl, and 2-oxopyrazin-1(2*H*)-yl) are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

each R^{61} is independently selected from methyl and fluoro;

each R^{c30} and R^{d30} is independently selected from H and methyl;

each R^{a31} is independently selected from H and methyl; and

each R^{a60}, R^{b60}, R^{c60} and R^{d60} is independently selected from H, C_{1-2} alkyl, C_1 haloalkyl, cyclopropyl, tetrahydrofuranyl, and thiazolyl; wherein said C_{1-2} alkyl, cyclopropyl, tetrahydrofuranyl, and thiazolyl are each optionally substituted with 1 or 2 substituents independently selected from R^{61};

or any R^{c60} and R^{d60} attached to the same N atom, together with the N atom to which they are attached, form an azetidinyl group optionally substituted with 1 or 2 substituents independently selected from R^{61}.

14. The use of any one of claims 9 to 13, wherein the compound of Formula I is a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof.

15. The use of any one of claims 9 to 14, wherein the compound of Formula I is a compound of Formula III:



III

or a pharmaceutically acceptable salt thereof.

16. The use of any one of claims 1 to 15, wherein the KRAS G12D inhibitor is selected from

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(7-chloro-3-hydroxynaphthalen-1-yl)-6-fluoro-2-methyl-4-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(5,7-difluoro-1H-indol-3-yl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(6-fluoro-5-methyl-1*H*-indol-3-yl)-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(2-(3-(Azetidin-1-yl)-3-oxopropyl)-1-((*1R,4R,5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-((1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)methyl)oxazolidin-2-one;

8-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-2,8-dimethyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

1-((2*S*,4*S*)-1-Acetyl-2-(cyanomethyl)piperidin-4-yl)-7-(8-cyanonaphthalen-1-yl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinoline-8-carbonitrile;

8-(1-((*1R*,*4R*,*5S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-((3-oxomorpholino)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(7-(Benzo[*b*]thiophen-3-yl)-1-((*1R*,*4R*,*5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-((2-oxopyrrolidin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((*1R*,*4R*,*5S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-4-(((*S*)-1-(dimethylamino)propan-2-yl)oxy)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((2-oxopyrrolidin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

8-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichloro-5-hydroxyphenyl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-4-((3-fluoro-1-methylazetidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-*N*,*N*-dimethylpropanamide;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methyl-4-(5-methylpyrazin-2-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-methyl-2-((4-methyl-2-oxopiperazin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichloro-5-hydroxyphenyl)-4-ethoxy-6-fluoro-2-((4-isopropyl-2-oxopiperazin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((3-oxomorpholino)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-4-ethoxy-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(1-(3-oxomorpholino)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((endo)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-(pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(2-(3-(azetidin-1-yl)-3-oxopropyl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(7,8-difluoronaphthalen-1-yl)-6-fluoro-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(2-(3-(azetidin-1-yl)-3-oxopropyl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(6,7-difluoronaphthalen-1-yl)-6-fluoro-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoro-3-hydroxynaphthalen-1-yl)-2-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

1-(1-((2*S*,4*S*)-1-Acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinolin-7-yl)isoquinoline-8-carbonitrile;

8-(1-((2*S*,4*S*)-1-acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

8-(1-((2*S*,4*S*)-1-acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoro-3-hydroxynaphthalen-1-yl)-2-methyl-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

(2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-c]quinolin-2-yl)-*N*,*N*-dimethylpyrrolidine-1-carboxamide;

methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2-chloro-3-methylphenyl)-8-(2-cyanoethyl)-6-fluoro-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (1S,3R,5S)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-2-(5-oxo-1,2,3,5-tetrahydroindolizin-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(methylcarbamoyl)pyridin-3-yl)-1H-pyrrolo[3,2-c] quinolin-2-yl)pyrrolidine-1-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2-chloro-3-fluorophenyl)-2-((R)-1-(cyclopropanecarbonyl)pyrrolidin-2-yl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

8-(2-((R)-1-Acetylpyrrolidin-2-yl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-8-methyl-4-(2-methylpyridin-4-yl)-1H-pyrrolo[3,2-c]quinolin-7-yl)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile;

5-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-8-(2-cyanoethyl)-6-fluoro-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-4-yl)-N-methylpicolinamide;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-6-fluoro-4-(5-methylpyrazin-2-yl)-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Ethyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-((R)-1-(3,3-difluoroazetidine-1-carbonyl)pyrrolidin-2-yl)-6-fluoro-4-(methyl-d3)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-((R)-1-(3,3-difluoroazetidine-1-carbonyl)pyrrolidin-2-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-6-fluoro-4-(5-methylpyrazin-2-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

5-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-4-yl)-N-methylpicolinamide;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(5-methylpyrazin-2-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (1R,3R,5R)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((*R*)-1-(2-oxopyrazin-1(2*H*)-yl)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

Methyl (2*R*,4*S*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-4-fluoropyrrolidine-1-carboxylate;

Methyl (2*R*,5*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-methylpyrrolidine-1-carboxylate;

Methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-3-chloro-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

4-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((*R*)-1-(2-oxopyrazin-1(2*H*)-yl)ethyl)-1*H*-pyrrolo[3,2-c]quinolin-4-yl)-2-fluoro-*N*-methylbenzamide;

Methyl ((1*R*)-1-(1-((*1R*,*4R*,*5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)carbamate;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-2,2-difluoroacetamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-2,2-difluoroacetamide;

(2*S*)-*N*-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)tetrahydrofuran-2-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)cyclopropanesulfonamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)thiazole-4-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-*N*-methylcyclopropanecarboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1*R*,3*R*,5*R*)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-fluorocyclopropane-1-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-fluorocyclobutane-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-2-(1-(2,6-dimethyl-3-oxo-2,3-dihydropyridazin-4-yl)ethyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)pyrimidine-4-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)pyridazine-3-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-3,3-difluoroazetidine-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-2-((*R*)-1-((1-methyl-1*H*-pyrazol-4-yl)amino)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

5-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((*R*)-1-(1-fluorocyclopropane-1-carbonyl)pyrrolidin-2-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-4-yl)-N,N-dimethylpicolinamide; and

methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(4-((dimethylamino)methyl)-2,3-difluorophenyl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

and pharmaceutically acceptable salts thereof.

17. The use of any one of claims 1 to 16, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-

azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

18. The use of any one of claims 1 to 17, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

19. The use of any one of claims 1 to 18, wherein the KRAS G12D inhibitor is 3-((R_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

20. The use of any one of claims 1 to 18, wherein the KRAS G12D inhibitor is 3-((S_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

21. The use of any one of claims 1 to 8, wherein the KRAS G12D inhibitor is a compound of Formula IV:



(**IV**)

or a pharmaceutically acceptable salt thereof, wherein:

Cy^1 is phenyl optionally substituted with 1, 2, 3, or 4 substituents each selected from D, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, OH, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

R^1 is halogen;

R^2 is selected from H, D, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-5} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3} alkylene, phenyl-C_{1-3} alkylene, 5-6 membered heteroaryl-C_{1-3} alkylene, halo, CN, OR^{a2}, $C(O)R^{b2}$, $C(O)NR^{c2}R^{d2}$, $NR^{c2}R^{e2}$, and $NR^{c2}C(O)R^{b2}$; wherein the C_{3-5} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, 4-6 membered heterocycloalkyl-C_{1-3}

alkylene, phenyl-C_{1-3} alkylene, and 5-6 membered heteroaryl-C_{1-3} alkylene forming R^2 are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2A}; wherein the ring-forming atoms of the 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, and 4-6 membered heterocycloalkyl-C_{1-3} alkylene forming R^2 consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C_{3-6} cycloalkyl-C_{1-3} alkylene, and 4-6 membered heterocycloalkyl-C_{1-3} alkylene forming R^2 is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^2 are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B};

each R^{a2} is independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein the C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl forming R^{a2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2A}; wherein the ring-forming atoms of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{a2} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{a2} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl forming R^{a2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B};

each R^{b2}, R^{c2}, and R^{d2} is independently selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl; wherein the C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl forming R^{b2}, R^{c2}, and R^{d2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2A}; the ring-forming atoms of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{b2}, R^{c2}, and R^{d2} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{b2}, R^{c2}, and R^{d2} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{b2}, R^{c2}, and R^{d2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B}; or

any R^{c2} and R^{d2} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B};

each R^{e2} is independently selected from C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl; wherein the C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl forming R^{e2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2A}; wherein the ring-forming atoms of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{e2} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-6 membered heterocycloalkyl and 5-6 membered heteroaryl forming R^{e2} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl, forming R^{e2} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B}; or

R^{c2} and R^{e2} attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, or 6-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from R^{2B};

each R^{2A} is independently selected from C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, and R^{2B}, wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl, forming R^{2A} are each optionally substituted with 1, 2 or 3 substituents independently selected from R^{2B};

each R^{2B} is independently selected from C_{3-6} cycloalkyl, 4-10 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a2B}, $C(O)R^{b2B}$, $C(O)NR^{c2B}R^{d2B}$, $C(O)OR^{a2B}$, $NR^{c2B}R^{d2B}$, and $S(O)_2R^{b2B}$; wherein the C_{1-3} alkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{2C};

each R^{2C} is independently selected from C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, halo, D, CN, OR^{a2C}, $C(O)R^{b2C}$, $C(O)NR^{c2C}R^{d2C}$, $C(O)OR^{a2C}$, $NR^{c2C}R^{d2C}$, and $S(O)_2R^{b2C}$;

each R^{a2B}, R^{b2B}, R^{c2B} and R^{d2B} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

each R^{a2C}, R^{b2C}, R^{c2C} and R^{d2C} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

R^3 is selected from C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, OR^{3A}, and $NR^{3B}R^{3C}$; wherein the C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl C_{1-3} alkyl forming R^3 are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3D}; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^3 consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 5-10 membered heteroaryl forming R^3 is

optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^3 are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3E};

R^{3A} is selected from C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl; wherein the C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl C_{1-3} alkyl forming R^{3A} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3D}; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^{3A} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl or 5-10 membered heteroaryl forming R^{3A} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{3A} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3E};

R^{3B} is selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl; wherein the C_{3-10} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl forming R^{3B} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3D}; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^{3B} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^{3B} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{3B} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3E};

R^{3B} and R^{3C}, together with the N atom to which they are both attached, optionally form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group that is optionally substituted with 1, 2, or 3 substituents independently selected from independently selected from R^{3D};

R^{3C} is selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl; wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{3C} are each optionally substituted with 1, 2, or 3 substituents independently selected from R^{3E};

each R^{3D} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, and R^{3E}; wherein each of the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{3D} is optionally substituted with 1, 2, or 3 substituents independently selected from R^{3E};

each R^{3E} is independently selected from D, halo, CN, OR^{a3}, SR^{a3}, $C(O)R^{b3}$, $C(O)NR^{c3}R^{d3}$, $C(O)OR^{a3}$, $OC(O)R^{b3}$, $OC(O)NR^{c3}R^{d3}$, $NR^{c3}R^{d3}$, $NR^{c3}C(O)R^{b3}$,

$NR^{c3}C(O)NR^{c3}R^{d3}$, $NR^{c3}C(O)OR^{a3}$, $C(=NR^{e3})NR^{c3}R^{d3}$, $NR^{c3}C(=NR^{e3})NR^{c3}R^{d3}$, $S(O)R^{b3}$, $S(O)NR^{c3}R^{d3}$, $S(O)_2R^{b3}$, $NR^{c3}S(O)_2R^{b3}$, and $S(O)_2NR^{c3}R^{d3}$;

R^{a3}, R^{b3}, R^{c3}, and R^{d3} are each independently selected from H, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl; wherein the C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3}, R^{b3}, R^{c3}, and R^{d3} are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, CN, OR^{a3A}, SR^{a3A}, $C(O)R^{b3A}$, $C(O)NR^{c3A}R^{d3A}$, $C(O)OR^{a3A}$, $OC(O)R^{b3A}$, $OC(O)NR^{c3A}R^{d3A}$, $NR^{c3A}R^{d3A}$, $NR^{c3A}C(O)R^{b3A}$, $NR^{c3A}C(O)NR^{c3A}R^{d3A}$, $NR^{c3A}C(O)OR^{a3A}$, $C(=NR^{e3A})NR^{c3A}R^{d3A}$, $NR^{c3A}C(=NR^{e3A})NR^{c3A}R^{d3A}$, $S(O)R^{b3A}$, $S(O)NR^{c3A}R^{d3A}$, $S(O)_2R^{b3A}$, $NR^{c3A}S(O)_2R^{b3A}$, and $S(O)_2NR^{c3A}R^{d3A}$; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3}, R^{b3}, R^{c3}, and R^{d3} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3}, R^{b3}, R^{c3}, and R^{d3} is optionally substituted by oxo to form a carbonyl group; or

R^{c3} and R^{d3} attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, CN, OR^{a3A}, SR^{a3A}, $C(O)R^{b3A}$, $C(O)NR^{c3A}R^{d3A}$, $C(O)OR^{a3A}$, $OC(O)R^{b3A}$, $OC(O)NR^{c3A}R^{d3A}$, $NR^{c3A}R^{d3A}$, $NR^{c3A}C(O)R^{b3A}$, $NR^{c3A}C(O)NR^{c3A}R^{d3A}$, $NR^{c3A}C(O)OR^{a3A}$, $C(=NR^{e3A})NR^{c3A}R^{d3A}$, $NR^{c3A}C(=NR^{e3A})NR^{c3A}R^{d3A}$, $S(O)R^{b3A}$, $S(O)NR^{c3A}R^{d3A}$, $S(O)_2R^{b3A}$, $NR^{c3A}S(O)_2R^{b3A}$, and $S(O)_2NR^{c3A}R^{d3A}$;

R^{a3A}, R^{b3A}, R^{c3A}, and R^{d3A} are each independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, aryl, C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl; wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3A}, R^{b3A}, R^{c3A}, and R^{d3A} are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NH(C_{1-6} alkyl), N(C_{1-6} alkyl)$_2$, halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3A}, R^{b3A}, R^{c3A}, and R^{d3A}

consist of at least one carbon atom, and 1, 2, 3, or 4 heteroatoms selected from O, N, and S; and wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{a3A}, R^{b3A}, R^{c3A}, and R^{d3A} is optionally substituted by oxo to form a carbonyl group; or

R^{c3A} and R^{d3A} attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NH(C_{1-6} alkyl), N(C_{1-6} alkyl)$_2$, halo, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy;R^{e3}, and R^{e3A} are each, independently, H, CN or NO_2;

each R^4 is independently selected from H, D, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, and OR^{a4};

each R^{a4} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

one R^5 is R^{5A}; and each other R^5 is independently selected from H, D, halo, C_{1-3} alkyl, OR^{a5}, C_{1-3} haloalkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl; or, optionally, two other R^5 attached to the same carbon atom, together with the carbon atom to which they are both attached, form a spiro C_{3-6} cycloalkyl ring that is optionally substituted with 1, 2, 3, or 4 substituents each selected from D, C_{1-3} alkyl, and halo; or, optionally, two other R^5 attached to adjacent carbon atoms, together with the carbon atoms to which they are each attached, form a fused C_{3-6} cycloalkyl ring that is optionally substituted with 1, 2, 3, or 4 substituents each selected from D, C_{1-3} alkyl, and halo;

R^{5A} is H, D, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, OR^{a5A}, CN, or Cy^2; wherein the C_{1-3} alkyl forming R^{5A} is optionally substituted with 1, 2, 3 or 4 substituents each selected from R^{5B} and also optionally substituted with Cy^2, or, optionally, R^{5A} and R^5 attached to the same carbon atom, together with the carbon atom to which they are both attached, form a spiro C_{3-6} cycloalkyl ring that is optionally substituted with 1, 2, 3, or 4 substituents each selected from D, C_{1-3} alkyl, and halo; or, optionally, R^{5A} and R^5 attached to adjacent carbon atoms, together with the carbon atoms to which they are each attached, form a fused C_{3-6} cycloalkyl ring that is optionally substituted with 1, 2, 3, or 4 substituents each selected from D, C_{1-3} alkyl, and halo;

each R^{5B} is independently selected from D and halo;

each R^{a5} is independently selected from H, C_{1-3} alkyl, and C_{1-3} haloalkyl;

R^{a5A} is selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, and Cy^2, wherein the C_{1-3} alkyl forming R^{a5A} is optionally substituted with 1, 2, 3 or 4 substituents each selected from R^{5B} and also optionally substituted with Cy^2;

Cy^2 is selected from C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl; wherein the C_{3-7} cycloalkyl, 4-10 membered heterocycloalkyl,

C_{6-10} aryl, 5-10 membered heteroaryl, C_{6-10} aryl, and 5-10 membered heteroaryl forming Cy^2 is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R^{Cy2}; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming Cy^2 consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S; and wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming Cy^2 is optionally substituted by oxo to form a carbonyl group;

each R^{Cy2} is independently selected from D, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{3-6} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl, halo, CN, OR^{aCy21}, SR^{aCy21}, $C(O)R^{bCy21}$, $C(O)NR^{cCy21}R^{dCy21}$, $C(O)OR^{aCy21}$, $OC(O)R^{bCy21}$, $OC(O)NR^{cCy21}R^{dCy21}$, $NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(O)R^{bCy21}$, $NR^{cCy21}C(O)NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(O)OR^{aCy21}$, $C(=NR^{eCy21})NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(=NR^{eCy21})NR^{cCy21}R^{dCy21}$, $S(O)R^{bCy21}$, $S(O)NR^{cCy21}R^{dCy21}$, $S(O)_2R^{bCy21}$, $NR^{cCy21}S(O)_2R^{bCy21}$, and $S(O)_2NR^{cCy21}R^{dCy21}$; wherein the C_{3-6} cycloalkyl, 4-10 membered heterocycloalkyl, C_{6-10} aryl, and 5-10 membered heteroaryl forming R^{Cy2} are each optionally substituted by 1, 2, 3, or 4 substituents independently selected from R^{Cy2A}; wherein the ring-forming atoms of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^{Cy2} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of the 4-10 membered heterocycloalkyl and 5-10 membered heteroaryl forming R^{Cy2} is optionally substituted by oxo to form a carbonyl group; and wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{Cy2} are each optionally substituted by 1, 2, or 3 substituents independently selected from R^{Cy2B};

each R^{Cy2A} is independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, and R^{Cy2B}; wherein the C_{1-3} alkyl, C_{2-3} alkenyl, and C_{2-3} alkynyl forming R^{Cy2A} are each optionally substituted by 1, 2, or 3 substituents independently selected from R^{Cy2B},

each R^{Cy2B} is independently selected from D, halo, CN, OR^{aCy21}, SR^{aCy21}, $C(O)R^{bCy21}$, $C(O)NR^{cCy21}R^{dCy21}$, $C(O)OR^{aCy21}$, $OC(O)R^{bCy21}$, $OC(O)NR^{cCy21}R^{dCy21}$, $NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(O)R^{bCy21}$, $NR^{cCy21}C(O)NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(O)OR^{aCy21}$, $C(=NR^{eCy21})NR^{cCy21}R^{dCy21}$, $NR^{cCy21}C(=NR^{eCy21})NR^{cCy21}R^{dCy21}$, $S(O)R^{bCy21}$, $S(O)NR^{cCy21}R^{dCy21}$, $S(O)_2R^{bCy21}$, $NR^{cCy21}S(O)_2R^{bCy21}$, and $S(O)_2NR^{cCy21}R^{dCy21}$,

R^{aCy21}, R^{bCy21}, R^{cCy21}, and R^{dCy21} are each independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{6-10} aryl, C_{3-7} cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl; wherein the C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy21}, R^{bCy21}, R^{cCy21}, and R^{dCy21} are each

optionally substituted with 1, 2, or 3 substituents independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, CN, OR^{aCy22}, SR^{aCy22}, $C(O)R^{bCy22}$, $C(O)NR^{cCy22}R^{dCy22}$, $C(O)OR^{aCy22}$, $OC(O)R^{bCy22}$, $OC(O)NR^{cCy22}R^{dCy22}$, $NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(O)R^{bCy22}$, $NR^{cCy22}C(O)NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(O)OR^{aCy22}$, $C(=NR^{eCy22})NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(=NR^{eCy22})NR^{cCy22}R^{dCy22}$, $S(O)R^{bCy22}$, $S(O)NR^{cCy22}R^{dCy22}$, $S(O)_2R^{bCy22}$, $NR^{cCy22}S(O)_2R^{bCy22}$, and $S(O)_2NR^{cCy22}R^{dCy22}$; wherein the ring-forming atoms each of the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy21}, R^{bCy21}, R^{cCy21}, and R^{dCy21} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S; and wherein a ring-forming carbon atom of the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy21}, R^{bCy21}, R^{cCy21}, and R^{dCy21} is optionally substituted by oxo to form a carbonyl group;

or R^{cCy21} and R^{dCy21} attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, halo, CN, OR^{aCy22}, SR^{aCy22}, $C(O)R^{bCy22}$, $C(O)NR^{cCy22}R^{dCy22}$, $C(O)OR^{aCy22}$, $OC(O)R^{bCy22}$, $OC(O)NR^{cCy22}R^{dCy22}$, $NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(O)R^{bCy22}$, $NR^{cCy22}C(O)NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(O)OR^{aCy22}$, $C(=NR^{eCy22})NR^{cCy22}R^{dCy22}$, $NR^{cCy22}C(=NR^{eCy22})NR^{cCy22}R^{dCy22}$, $S(O)R^{bCy22}$, $S(O)NR^{cCy22}R^{dCy22}$, $S(O)_2R^{bCy22}$, $NR^{cCy22}S(O)_2R^{bCy22}$, and $S(O)_2NR^{cCy22}R^{dCy22}$;

R^{aCy22}, R^{bCy22}, R^{cCy22}, and R^{dCy22} are each independently selected from H, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, aryl, C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl; wherein the C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{6-10} aryl-C_{1-3} alkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, C_{3-7} cycloalkyl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy22}, R^{bCy22}, R^{cCy22}, and R^{dCy22} are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, NH(C_{1-3} alkyl), N(C_{1-3} alkyl)$_2$, halo, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, and C_{1-3} haloalkoxy; wherein the ring-forming atoms each of the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy22}, R^{bCy22}, R^{cCy22}, and R^{dCy22} consist of at least one carbon atom and 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S; and wherein a ring-forming carbon atom of the 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl-C_{1-3} alkyl, and 4-10 membered heterocycloalkyl-C_{1-3} alkyl forming R^{aCy22}, R^{bCy22}, R^{cCy22}, and R^{dCy22} is optionally substituted by oxo to form a carbonyl group; or

R^{cCy22} and R^{dCy22} attached to the same N atom, together with the N atom to which they are both attached, form a 4-, 5-, 6-, or 7-membered heterocycloalkyl group or 5-membered heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, $NH(C_{1-6}$ alkyl), $N(C_{1-6}$ alkyl)$_2$, halo, C_{1-3} alkyl, C_{1-3} alkoxy, C_{1-3} haloalkyl, and C_{1-3} haloalkoxy; and

R^{eCy21} and R^{eCy22} are each, independently, H, CN or NO_2.

22. The use of any one of claims 1 to 8 and 21, wherein

Cy^1 is phenyl optionally substituted with 1 or 2 substituents each selected from D, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, OH, and C_{1-3} alkoxy;

R^1 is halo;

R^2 is C_{1-3} alkyl optionally substituted with OH;

R^3 is C_{3-10} cycloalkyl optionally substituted with halo;

each R^4 is H;

one R^5 is R^{5A}; and each other R^5 is independently selected from H, D, halo, C_{1-3} alkyl, OC_{1-3} alkyl, C_{1-3} haloalkyl; or, optionally, two other R^5 attached to adjacent carbon atoms, together with the carbon atoms to which they are each attached, form a fused C_{3-6} cycloalkyl ring that is optionally substituted with 1 or 2 substituents each selected from D, C_{1-3} alkyl, and halo; and

R^{5A} is H, halo, or OR^{a5A};

R^{a5A} is selected from C_{1-3} alkyl, C_{1-3} haloalkyl, and Cy^2, wherein the C_{1-3} alkyl forming R^{a5A} is optionally substituted with 1, 2, or 3 D, and also optionally substituted with Cy^2; and

Cy^2 is selected from C_{6-10} aryl and 5-10 membered heteroaryl.

23. The use of any one of claims 1 to 8, 21, and 22, wherein

Cy^1 is phenyl optionally substituted with 1 or 2 substituents each selected from D, C_{1-3} alkyl, C_{1-3} haloalkyl, halo, OH, and C_{1-3} alkoxy;

R^1 is halo;

R^2 is C_{1-3} alkyl optionally substituted with OH;

R^3 is OR^{3A} or C_{3-10} cycloalkyl optionally substituted with halo;

R^{3A} is C_{1-3} alkyl;

each R^4 is H;

one R^5 is R^{5A}; and each other R^5 is independently selected from H, D, halo, C_{1-3} alkyl, OC_{1-3} alkyl, C_{1-3} haloalkyl; or, optionally, two other R^5 attached to adjacent carbon atoms, together with the carbon atoms to which they are each attached, form a fused C_{3-6} cycloalkyl ring that is optionally substituted with 1 or 2 substituents each selected from D, C_{1-3} alkyl, and halo;

R^{5A} is H, halo, or OR^{a5A};

R^{a5A} is selected from C_{1-3} alkyl, C_{1-3} haloalkyl, and Cy^2, wherein the C_{1-3} alkyl forming R^{a5A} is optionally substituted with 1, 2, or 3 D, and also optionally substituted with Cy^2; and

Cy^2 is selected from C_{6-10} aryl and 5-10 membered heteroaryl.

24. The use of any one of claims 1 to 8 and 21 to 23, wherein

Cy^1 is phenyl optionally substituted with 1 or 2 substituents each selected from C_{1-3} alkyl, C_{1-3} haloalkyl, halo, OH, and C_{1-3} alkoxy;

R^1 is halo;

R^2 is C_{1-3} alkyl optionally substituted with OH;

R^3 is OR^{3A} or C_{3-10} cycloalkyl optionally substituted with halo;

R^{3A} is C_{1-3} alkyl;

each R^4 is H;

one R^5 is R^{5A}; and each other R^5 is independently selected from H, halo, C_{1-3} alkyl, OC_{1-3} alkyl, C_{1-3} haloalkyl;

R^{5A} is H, halo, or OR^{a5A}; and

R^{a5A} is selected from C_{1-3} alkyl and C_{1-3} haloalkyl, wherein the C_{1-3} alkyl forming R^{a5A} is optionally substituted with 1, 2, or 3 D.

25. The use of any one of claims 1 to 8 and 21 to 24, wherein the compound of Formula IV is a compound of Formula IV-A or Formula IV-B:



(**IV-A**)



(**IV-B**)

or a pharmaceutically acceptable salt thereof.

26. The use of any one of claims 1 to 8 and 21 to 25, wherein the compound of Formula IV is selected from

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-methoxy-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-fluoro-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(6-(cyclopropanecarbonyl)-6-azatricyclo[3.2.1.02,4]octan-7-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(methoxy-d3)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(pyridin-3-yloxy)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(2-(5-(benzyloxy)-2-(cyclopropanecarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-(5-fluoro-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-4-((R)-1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(difluoromethyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

5-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-2-(2-(cyclopropanecarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-4-yl)-N,N-dimethylpicolinamide;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

4-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-2-(2-(cyclopropanecarbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-4-yl)-2-fluoro-N-methylbenzamide;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-methyl-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-hydroxy-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(pyridin-2-yloxy)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(pyridin-4-yloxy)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-(5-(difluoromethoxy)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-(5-fluoro-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(5-chloro-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-(trifluoromethoxy)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-(5-(difluoromethoxy)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(2-(cyclopropanecarbonyl)-5-cyclopropoxy-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-(5-(difluoromethoxy)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-6-fluoro-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-2-(5-cyclopropoxy-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

methyl 3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-2-yl)-5-(trifluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate;

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-(2-(1-fluorocyclopropane-1-carbonyl)-5-(trifluoromethoxy)-2-azabicyclo[2.2.1]heptan-3-yl)-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

methyl 3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-2-yl)-5-(difluoromethyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate; and

3-(1-(2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-(5-(difluoromethyl)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[2.2.1]heptan-3-yl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

and pharmaceutically acceptable salts thereof.

27. The use of any one of claims 1 to 8 and 21 to 26, wherein the compound of Formula IV is methyl (1*R*,3*R*,4*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof.

28. The use of any one of claims 1 to 27, wherein the KRAS G12D inhibitor is to be administered in a pharmaceutical composition comprising the KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

29. The use of any one of claims 1 to 28, wherein the EGFR inhibitor is to be administered in a pharmaceutical composition comprising the EGFR inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient.

30. Use of:

a pharmaceutical composition comprising a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient; and

a pharmaceutical composition comprising an EGFR inhibitor, or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient,

in the manufacture of a medicament for treating cancer.

31. Use of a KRAS G12D inhibitor that is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor that is cetuximab in the manufacture of a medicament for treating cancer.

32. The use of claim 31, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

33. The use of claim 31 or 32, wherein the KRAS G12D inhibitor is 3-((R_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

34. The use of claim 31 or 32, wherein the KRAS G12D inhibitor is 3-((S_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

35. Use of a KRAS G12D inhibitor that is methyl (1*R*,3*R*,4*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor that is cetuximab in the manufacture of a medicament for treating cancer.

36. The use of any one of claims 1 to 35, wherein the KRAS G12D inhibitor is to be administered twice daily (BID).

37. The use of any one of claims 1 to 35, wherein the KRAS G12D inhibitor is to be administered once daily (QD).

38. The use of any one of claims 1 to 37, wherein the KRAS G12D inhibitor is to be administered orally (PO).

39. The use of any one of claims 1 to 38, wherein the EGFR inhibitor is to be administered twice a week (BIW).

40. The use of any one of claims 1 to 39, wherein the EGFR inhibitor is to be administered as an intravenous injection (IV).

41. The use of any one of claims 1 to 40, wherein the cancer is selected from carcinomas, hematological cancers, sarcomas, and glioblastoma.

42. The use of any one of claims 1 to 41, wherein the cancer is a cancer comprising abnormally proliferating cells having a KRAS G12D mutation.

43. The use of any one of claims 1 to 41, wherein the use further comprises identifying that abnormally proliferating cells of the cancer comprise a KRAS G12D mutation.

44. The use of any one of claims 41 to 43, wherein the cancer is a hematological cancer selected from myeloproliferative neoplasms, myelodysplastic syndrome, chronic and juvenile myelomonocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, and multiple myeloma.

45. The use of any one of claims 41 to 43, wherein the cancer is a carcinoma selected from pancreatic, colorectal, lung, bladder, gastric, esophageal, breast, head and neck, cervical, skin, and thyroid carcinomas.

46. The use of claim 45, wherein the carcinoma is colorectal carcinoma.

47. The use of claim 45, wherein the carcinoma is lung carcinoma.

48. The use of claim 45, wherein the carcinoma is pancreatic carcinoma.

49. The use of any one of claims 1 to 43, wherein the cancer is colorectal cancer.

50. The use of any one of claims 1 to 43, wherein the cancer is non-small cell lung cancer (NSCLC).

51. The use of any one of claims 1 to 43, wherein the cancer is pancreatic ductal adenocarcinoma.

52. The use of any one of claims 1 to 51, wherein the cancer is metastatic.

53. A pharmaceutical composition comprising

a) a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof;

b) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof; and

c) at least one pharmaceutically acceptable carrier or excipient.

54. The pharmaceutical composition of claim 53, wherein the KRAS G12D inhibitor is selected from

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(7-chloro-3-hydroxynaphthalen-1-yl)-6-fluoro-2-methyl-4-(1H-1,2,4-triazol-1-yl)-1H-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(5,7-difluoro-1H-indol-3-yl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(6-fluoro-5-methyl-1*H*-indol-3-yl)-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(2-(3-(Azetidin-1-yl)-3-oxopropyl)-1-((*1R,4R,5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-((1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)methyl)oxazolidin-2-one;

8-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-2,8-dimethyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

1-((2*S*,4*S*)-1-Acetyl-2-(cyanomethyl)piperidin-4-yl)-7-(8-cyanonaphthalen-1-yl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinoline-8-carbonitrile;

8-(1-((*1R*,*4R*,*5S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-8-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-((3-oxomorpholino)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(7-(Benzo[*b*]thiophen-3-yl)-1-((*1R*,*4R*,*5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-((2-oxopyrrolidin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((*1R*,*4R*,*5S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-4-(((*S*)-1-(dimethylamino)propan-2-yl)oxy)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((2-oxopyrrolidin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

8-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichloro-5-hydroxyphenyl)-6-fluoro-2-methyl-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-4-((3-fluoro-1-methylazetidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-*N*,*N*-dimethylpropanamide;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-methyl-4-(5-methylpyrazin-2-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-methyl-2-((4-methyl-2-oxopiperazin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichloro-5-hydroxyphenyl)-4-ethoxy-6-fluoro-2-((4-isopropyl-2-oxopiperazin-1-yl)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-4-(3-(dimethylamino)-3-methylazetidin-1-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((3-oxomorpholino)methyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-4-ethoxy-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-2-(1-(3-oxomorpholino)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((endo)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-2-(pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(2-(3-(azetidin-1-yl)-3-oxopropyl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(7,8-difluoronaphthalen-1-yl)-6-fluoro-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(2-(3-(azetidin-1-yl)-3-oxopropyl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(6,7-difluoronaphthalen-1-yl)-6-fluoro-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoro-3-hydroxynaphthalen-1-yl)-2-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

1-(1-((2*S*,4*S*)-1-Acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinolin-7-yl)isoquinoline-8-carbonitrile;

8-(1-((2*S*,4*S*)-1-acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrrolo[3,2-*c*]quinolin-7-yl)-1-naphthonitrile;

8-(1-((2*S*,4*S*)-1-acetyl-2-(cyanomethyl)piperidin-4-yl)-8-chloro-6-fluoro-4-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-1*H*-pyrazolo[4,3-*c*]quinolin-7-yl)-1-naphthonitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoro-3-hydroxynaphthalen-1-yl)-2-methyl-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-methyl-4-((S)-1-((S)-1-methylpyrrolidin-2-yl)ethoxy)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

(2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-c]quinolin-2-yl)-*N*,*N*-dimethylpyrrolidine-1-carboxamide;

methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2-chloro-3-methylphenyl)-8-(2-cyanoethyl)-6-fluoro-4-(1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (1S,3R,5S)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-2-(5-oxo-1,2,3,5-tetrahydroindolizin-3-yl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(methylcarbamoyl)pyridin-3-yl)-1H-pyrrolo[3,2-c] quinolin-2-yl)pyrrolidine-1-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2-chloro-3-fluorophenyl)-2-((R)-1-(cyclopropanecarbonyl)pyrrolidin-2-yl)-6-fluoro-4-methyl-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

8-(2-((R)-1-Acetylpyrrolidin-2-yl)-1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-8-methyl-4-(2-methylpyridin-4-yl)-1H-pyrrolo[3,2-c]quinolin-7-yl)-1,2,3,4-tetrahydronaphthalene-1-carbonitrile;

5-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-8-(2-cyanoethyl)-6-fluoro-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-4-yl)-N-methylpicolinamide;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-6-fluoro-4-(5-methylpyrazin-2-yl)-2-((R)-1-(2-oxopyrazin-1(2H)-yl)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(5-fluoro-6-(methylcarbamoyl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Methyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

Ethyl (2R)-2-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1H-pyrrolo[3,2-c]quinolin-2-yl)pyrrolidine-1-carboxylate;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-((R)-1-(3,3-difluoroazetidine-1-carbonyl)pyrrolidin-2-yl)-6-fluoro-4-(methyl-d3)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-2-((R)-1-(3,3-difluoroazetidine-1-carbonyl)pyrrolidin-2-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-6-fluoro-4-(5-methylpyrazin-2-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

5-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-4-yl)-N-methylpicolinamide;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

3-(1-((1R,4R,5S)-2-Azabicyclo[2.1.1]hexan-5-yl)-6-fluoro-7-(7-fluoronaphthalen-1-yl)-4-(5-methylpyrazin-2-yl)-2-((R)-1-(3-oxomorpholino)ethyl)-1H-pyrrolo[3,2-c]quinolin-8-yl)propanenitrile;

Methyl (1R,3R,5R)-3-(1-((1R,4R,5S)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(6-(dimethylcarbamoyl)pyridin-3-yl)-6-fluoro-1H-pyrrolo[3,2-c]quinolin-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-2-((*R*)-1-(2-oxopyrazin-1(2*H*)-yl)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

Methyl (2*R*,4*S*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-4-fluoropyrrolidine-1-carboxylate;

Methyl (2*R*,5*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-methylpyrrolidine-1-carboxylate;

Methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-3-chloro-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

4-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((*R*)-1-(2-oxopyrazin-1(2*H*)-yl)ethyl)-1*H*-pyrrolo[3,2-c]quinolin-4-yl)-2-fluoro-*N*-methylbenzamide;

Methyl ((1*R*)-1-(1-((*1R*,*4R*,*5S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)carbamate;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-2,2-difluoroacetamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-2,2-difluoroacetamide;

(2*S*)-*N*-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)tetrahydrofuran-2-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)cyclopropanesulfonamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)thiazole-4-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-*N*-methylcyclopropanecarboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-methylcyclopropane-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-2-((1*R*,3*R*,5*R*)-2-(1-methylcyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

3-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((1*R*,3*R*,5*R*)-2-(1-fluorocyclopropane-1-carbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-fluorocyclopropane-1-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-(1-hydroxyethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-1-fluorocyclobutane-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(3-chloro-2-methylphenyl)-2-(1-(2,6-dimethyl-3-oxo-2,3-dihydropyridazin-4-yl)ethyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)pyrimidine-4-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)pyridazine-3-carboxamide;

N-((1*R*)-1-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)ethyl)-3,3-difluoroazetidine-1-carboxamide;

3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-2-((*R*)-1-((1-methyl-1*H*-pyrazol-4-yl)amino)ethyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile;

5-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-2-((*R*)-1-(1-fluorocyclopropane-1-carbonyl)pyrrolidin-2-yl)-1*H*-pyrrolo[3,2-*c*]quinolin-4-yl)-N,N-dimethylpicolinamide; and

methyl (2*R*)-2-(1-((1*R*,4*R*,5*S*)-2-Azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-4-(4-((dimethylamino)methyl)-2,3-difluorophenyl)-6-fluoro-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)pyrrolidine-1-carboxylate;

and pharmaceutically acceptable salts thereof.

55. The pharmaceutical composition of claim 53 or 54, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

56. The pharmaceutical composition of any one of claims 53 to 55, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

57. The pharmaceutical composition of any one of claims 53 to 56, wherein the KRAS G12D inhibitor is 3-((R_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

58. The pharmaceutical composition of any one of claims 53 to 56, wherein the KRAS G12D inhibitor is 3-((S_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

59. The pharmaceutical composition of claim 53, wherein the KRAS G12D inhibitor is methyl (1*R*,3*R*,4*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof.

60. The pharmaceutical composition of any one of claims 53 to 59, wherein the EGFR inhibitor is cetuxmiab.

61. A pharmaceutical combination comprising a KRAS G12D inhibitor, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor, or pharmaceutically acceptable salt thereof.

62. The pharmaceutical combination of claim 61, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile, or a pharmaceutically acceptable salt thereof.

63. The pharmaceutical combination of claim 61 or 62, wherein the KRAS G12D inhibitor is 3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-

2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

64. The pharmaceutical combination of any one of claims 61 to 63, wherein the KRAS G12D inhibitor is 3-((R_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

65. The pharmaceutical combination of any one of claims 61 to 63, wherein the KRAS G12D inhibitor is 3-((S_a)-1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-2-((1*R*,3*R*,5*R*)-2-(cyclopropanecarbonyl)-2-azabicyclo[3.1.0]hexan-3-yl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)propanenitrile hydrochloride dihydrate.

66. The pharmaceutical combination of claim 61, wherein the KRAS G12D inhibitor is methyl (1*R*,3*R*,4*R*,5*S*)-3-(1-((1*R*,4*R*,5*S*)-2-azabicyclo[2.1.1]hexan-5-yl)-8-(2-cyanoethyl)-7-(2,3-dichlorophenyl)-6-fluoro-4-methyl-1*H*-pyrrolo[3,2-*c*]quinolin-2-yl)-5-(difluoromethoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof.

67. The pharmaceutical combination of any one of claims 61 to 66, wherein the EGFR inhibitor is cetuximab.